Provided by Tiger Trade Technology Pte. Ltd.

Atea Pharmaceuticals, Inc.

5.12
-0.2100-3.94%
Post-market: 5.120.00000.00%19:52 EDT
Volume:320.15K
Turnover:1.65M
Market Cap:407.92M
PE:-2.64
High:5.40
Open:5.33
Low:5.08
Close:5.33
52wk High:6.45
52wk Low:2.46
Shares:79.67M
Float Shares:59.51M
Volume Ratio:0.57
T/O Rate:0.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9430
EPS(LYR):-1.9430
ROE:-44.34%
ROA:-28.75%
PB:1.48
PE(LYR):-2.64

Loading ...

Atea Pharmaceuticals Inc - C-Beyond Topline Results Expected Mid-2026

THOMSON REUTERS
·
Dec 22, 2025

Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

THOMSON REUTERS
·
Dec 22, 2025

Nano Dimension And 2 Other Penny Stocks With Promising Potential

Simply Wall St.
·
Dec 18, 2025

Atea Pharmaceuticals to Present at Evercore Healthcare Conference

Reuters
·
Nov 19, 2025

3 Promising Penny Stocks With Market Caps As Low As $200M

Simply Wall St.
·
Nov 13, 2025

Atea Pharmaceuticals Advances Antiviral Programs with New Data

TIPRANKS
·
Nov 13, 2025

Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Announces Progress in Hepatitis C and E Programs

Reuters
·
Nov 13, 2025

Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire
·
Nov 13, 2025

Atea Pharmaceuticals announces presentation of data on BEM, RZR

TIPRANKS
·
Nov 07, 2025

Atea Pharmaceuticals Unveils Promising Phase 2 Data for Bemnifosbuvir and Ruzasvir Hepatitis C Treatment

Reuters
·
Nov 07, 2025

Atea Pharmaceuticals Inc. to Report Third Quarter 2025 Financial Results

Reuters
·
Nov 05, 2025

Atea Pharmaceuticals Inc expected to post a loss of 44 cents a share - Earnings Preview

Reuters
·
Nov 04, 2025

Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025

GlobeNewswire
·
Oct 22, 2025

Atea Pharmaceuticals to present data on bemnifosbuvir, ruzasvir combination

TIPRANKS
·
Oct 07, 2025

Atea Pharmaceuticals Announces Promising New Data for Bemnifosbuvir and Ruzasvir Combination in Hepatitis C Treatment at The Liver Meeting® 2025

Reuters
·
Oct 07, 2025